Related Experiment Videos
Practical aspects in the use of cyclosporin in paediatric nephrology
P F Hoyer1, J Brodehl, J H Ehrich
1Department of Paediatric Nephrology and Metabolic Diseases, Children's Hospital, Medical School Hannover, Federal Republic of Germany.
Insights
Cyclosporin A (CsA) is effective in pediatric nephrology, but requires careful dosing and monitoring. Understanding its pharmacokinetics and potential drug interactions is crucial for safe and effective use in children.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
Background:
- Cyclosporin A (CsA) is an immunosuppressant used in pediatric nephrology.
- Effective use requires understanding its complex pharmacokinetics, including bioavailability, distribution, and metabolism.
- Factors like liver dysfunction and drug interactions can significantly alter CsA activity.
Purpose of the Study:
- To outline key considerations for the safe and effective use of CsA in pediatric nephrology.
- To provide guidance on dosing, drug monitoring, and managing potential complications.
- To review CsA's role in specific pediatric renal conditions.
Main Methods:
- Review of pharmacokinetic principles relevant to CsA in children.
- Analysis of factors influencing CsA metabolism and efficacy.
- Discussion of therapeutic drug monitoring strategies and target levels.
- Examination of clinical applications in renal transplantation and nephrotic syndrome.
Main Results:
- Body surface area-based dosing is recommended over weight-based dosing for pediatric renal transplant patients.
- Whole blood monitoring of the parent drug level is preferred over plasma.
- Therapeutic trough levels for CsA in steroid-dependent minimal change nephrotic syndrome are 80-160 ng/ml.
Conclusions:
- Careful consideration of CsA pharmacokinetics, drug interactions, and monitoring is essential for pediatric patients.
- Appropriate dosing and monitoring strategies can optimize efficacy and minimize toxicity.
- Further controlled trials are needed to confirm CsA's efficacy in conditions like lupus erythematosus.
Abstract:
Many factors must be considered for the effective and safe use of cyclosporin A (CsA) in paediatric nephrology. Detailed knowledge of the variable bioavailability, tissue distribution, and metabolism, as well as causes which lead to their alteration are necessary. Factors which affect the activity of the mixed function oxidase system cytochrome P-450 must be considered, i.e. liver dysfunction and many drugs. Precise knowledge of the CsA determination method and the spectrum of metabolites is essential. In children with renal transplants, a body surface area-related dose will better meet the dose requirements than a body weight related-dose. For drug level monitoring whole blood rather than plasma should be used, and the parent drug level should be the main determinant; elevated metabolite levels may be important in suspected nephrotoxicity or liver dysfunction. Pharmacokinetic profiles are necessary to discover absorption problems or increased CsA clearance rates which necessitate shorter dosing intervals. In children with steroid-dependent minimal change nephrotic syndrome, remission without steroids is maintained as long as CsA is given. The appropriate starting dosage is 150 mg/m2 per day; trough level monitoring is mandatory to prevent nephrotoxicity and to confirm adequate immunosuppressive drug levels which should be 80-160 ng/ml (parent drug level). Although the benefit of CsA has been reported in some cases of lupus erythematosus, its use should be restricted to severe cases only until its efficacy and safety has been confirmed in controlled trials.